 "Sun Pharma launches Gleevec's generic in US")
Sun Pharma has launched imatinib mesylate tablet, the generic version of Novartis’ Gleevac, in US market. Sun Pharma’s subsidiary had received final approval for imatinib mesylate from US FDA in December 2015. Being a First-to-File product, it was granted 180 days of marketing exclusivity by FDA from the time of its launch.
As part of this launch, in addition to strengthening distribution in the US, the company has rolled-out unique Sun Pharma Imatinib Mesylate Savings Card program. This program aims to deliver greater access to the drug for patients who have a commercial insurance but their out-of-pocket may exceed an affordable amount.
“The savings card will reduce patient’s co-payment (out-of-pocket) to $10. In line with its philosophy of putting patients first, Sun Pharma’s Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to $ 700 for a 30-day fill to offset any additional out-of-pocket cost should they be required to meet their deductible or co-insurance. Participating pharmacies across USA can use the patient’s Sun Pharma’s Imatinib Mesylate Savings Card as part of this program,” said Sun Pharma in a press release.
As per IMS MAT August 2015, imatinib mesylate tablets (100 mg and 400 mg) have annual sales of approximately $ 2.5 billion in the US. These tablets are indicated for the treatment of chronic myeloid leukemia.
Sun Pharma has established a hub service where patients can dial-in to speak with a trained healthcare professional and discuss imatinib mesylate when used for indications approved by FDA under Sun Pharma’s ANDA.
As part of this launch, in addition to strengthening distribution in the US, the company has rolled-out unique Sun Pharma Imatinib Mesylate Savings Card program. This program aims to deliver greater access to the drug for patients who have a commercial insurance but their out-of-pocket may exceed an affordable amount.
“The savings card will reduce patient’s co-payment (out-of-pocket) to $10. In line with its philosophy of putting patients first, Sun Pharma’s Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to $ 700 for a 30-day fill to offset any additional out-of-pocket cost should they be required to meet their deductible or co-insurance. Participating pharmacies across USA can use the patient’s Sun Pharma’s Imatinib Mesylate Savings Card as part of this program,” said Sun Pharma in a press release.
As per IMS MAT August 2015, imatinib mesylate tablets (100 mg and 400 mg) have annual sales of approximately $ 2.5 billion in the US. These tablets are indicated for the treatment of chronic myeloid leukemia.
Sun Pharma has established a hub service where patients can dial-in to speak with a trained healthcare professional and discuss imatinib mesylate when used for indications approved by FDA under Sun Pharma’s ANDA.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%